Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Asahi Kasei Pharma Reports Strong Growth for April-December 2012; Sales of Teribone Break 12 Billion Yen Mark
February 8, 2013
- Pfizer Confident about Joining Top 3 in Japan Generic Sales by around 2015: Unit Chief Matsumori
February 7, 2013
- DSP President Expects Launch of PMDA-WEST, Says Kansai Firms Are at Disadvantage
February 7, 2013
- EMA Approves Otsuka’s Abilify for the Treatment of Manic Episodes in Bipolar I Disorder in Adolescents
February 7, 2013
- 4 Major Wholesalers’ Price Settlement Rates Lower than 2 Years Ago, Negotiations Charging into Final Phase: April-Dec. Earnings
February 7, 2013
- Novartis Jettisons Key Evidence from Diovan Promotion
February 6, 2013
- Sales and Profits Jump for Shionogi in April-December with US Sales Recovery
February 6, 2013
- Latuda Serves as Driving Force for Growth in North American Market: DSP President Tada
February 6, 2013
- Takeda Lowers Full-Year Sales Forecast for Nesina, but Says Nesina Remains “Fastest-Growing DPP-4 Inhibitor”
February 6, 2013
- Sales in Emerging Markets Contribute to Growth in Sales for April-December Despite Fall in Sales of All 4 Major Products: Takeda
February 6, 2013
- Daiichi Sankyo Starts PIII Trial of ARQ 197 in HCC Patients
February 5, 2013
- DSP Posts 46.5 % Rise in April-December Operating Profit Despite Japan Sales Fall
February 5, 2013
- Nesp, Mircera Jostling for Market Shares of Pre-Dialysis CKD Patients
February 5, 2013
- Teijin Pharma Appoints Hiroshi Uno as New President Effective from April 1
February 5, 2013
- 13.9 Bil. in Royalties from Gilenya Help Boost Consolidated Sales for April-December: MTPC
February 5, 2013
- Kyowa Kirin Posts Record Operating Profit for 2012; Sales Up 9% in Pharma Division
February 5, 2013
- Eisai’s Operating Profit Drops 34% in April-December as Aricept Sales Fall
February 4, 2013
- Aricept Fails to Meet Minimum Sales Target in Japan: Eisai
February 4, 2013
- Astellas April-Dec. Earnings: XTANDI Starts Off on Good Note, Could Outstrip Full-Year Target
February 4, 2013
- Kyowa Kirin to Launch 3 In-House Products in Europe and US, Aims for Sales of 358 Billion Yen in 2015: New Midterm Plan
February 4, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…